(Total Views: 739)
Posted On: 04/01/2021 12:51:57 PM
Post# of 36547
Joe's vision has turned into a swiss cheese. His financial roulette has not been rewarded and trust/credibility diminished. This stock doesn't fly under the radar it has no fuel to fly ! Covid remains the excuse , if a business plan looks reasonable, credible seasoned leadership and revenue estimates reachable than legit banking will probably fund the operation. Looks like no interest to finance current projects except vaccine research ........so let's try to use potential Vaccine success and or IPO funds to facilitate the ongoing 0 revenue subsidiaries. Q2 was another disaster, I'm pretty sure dilution will continue and Total Outstanding shares increase. No leadership shown in the shareholders NUGX concern and to clear up future doubts. Hard to believe Management was not aware ..... just like the CMP failure and other "unexpected" outcomes. How many dividends were issued to the "friendly" shares ? Investors are aware of this Company, just no interest imo and concerns of direction and Management vision.
Q2 note 1
(How many employees )??
Note 1 – Organization of Business and Going Concern
Generex Biotechnology Corporation (“Generex”, “Company”, “GNBT”, "we", "us" or "our"
, was formed in the State of Delaware on September 4, 1997 and its year-end is July 31. As of January 31, 2021, the active wholly-owned subsidiaries of the Company are Generex Pharmaceuticals, Inc.; 1097346 Ontario, Inc.; Nugenerex Diagnostics, Inc.; Rapid Medical Diagnostics Corporation; GNBTELC, LLC; Olaregen Therapeutix, Inc.; Nugenerex Management Services, Inc.; Nugenerex Distribution Solutions 2, LLC; DMEiq, LLC (d/b/a DME-IQ); Rapport Services, LLC; NMSIELC, LLC; High Desert Diagnostic Laboratory, Inc.; NuGenerex Distribution Solutions, LLC; Pantheon F & A, LLC; Nugenerex Surgical Holdings, LLC; NuGenerex Health, LLC; NuGenerex HMO, LLC; and NuGenerex MSO, LLC . NuGenerex Immuno-Oncology, Inc.; Regentys Corporation; and NuGenHealth, LLC are majority controlled subsidiaries.
Part of Note 7......
Note 7 – Notes Payable
As of January 31, 2021, and July 31, 2020, the Company had notes payable with aggregate principal balances of $10,641,832 and $11,591,479 and debt discounts of $85,078 and $425,120, respectively. The notes bear interest between 1% and 16% per annum. During the six months ended January 31, 2021, the Company made payments on principal of $127,459 and converted $1,077,452 of principal into common stock. As of January 31, 2021, there were two notes in default with an aggregate principal balance of $2,882,000 and are accruing at default rates of interest of 22% and 24% per annum.
Generex is an ATM with GNBT shares !
https://www.sec.gov/cgi-bin/browse-edgar?CIK=...er=exclude
This board has many opinions and assumptions .....imo we need seasoned leadership and von Hofe is the key to survival !! Credibility and trust need to be restored !
How many more delays/excuses/note conversions are acceptable ??
Q2 note 1
(How many employees )??
Note 1 – Organization of Business and Going Concern
Generex Biotechnology Corporation (“Generex”, “Company”, “GNBT”, "we", "us" or "our"
, was formed in the State of Delaware on September 4, 1997 and its year-end is July 31. As of January 31, 2021, the active wholly-owned subsidiaries of the Company are Generex Pharmaceuticals, Inc.; 1097346 Ontario, Inc.; Nugenerex Diagnostics, Inc.; Rapid Medical Diagnostics Corporation; GNBTELC, LLC; Olaregen Therapeutix, Inc.; Nugenerex Management Services, Inc.; Nugenerex Distribution Solutions 2, LLC; DMEiq, LLC (d/b/a DME-IQ); Rapport Services, LLC; NMSIELC, LLC; High Desert Diagnostic Laboratory, Inc.; NuGenerex Distribution Solutions, LLC; Pantheon F & A, LLC; Nugenerex Surgical Holdings, LLC; NuGenerex Health, LLC; NuGenerex HMO, LLC; and NuGenerex MSO, LLC . NuGenerex Immuno-Oncology, Inc.; Regentys Corporation; and NuGenHealth, LLC are majority controlled subsidiaries. Part of Note 7......
Note 7 – Notes Payable
As of January 31, 2021, and July 31, 2020, the Company had notes payable with aggregate principal balances of $10,641,832 and $11,591,479 and debt discounts of $85,078 and $425,120, respectively. The notes bear interest between 1% and 16% per annum. During the six months ended January 31, 2021, the Company made payments on principal of $127,459 and converted $1,077,452 of principal into common stock. As of January 31, 2021, there were two notes in default with an aggregate principal balance of $2,882,000 and are accruing at default rates of interest of 22% and 24% per annum.
Generex is an ATM with GNBT shares !
https://www.sec.gov/cgi-bin/browse-edgar?CIK=...er=exclude
This board has many opinions and assumptions .....imo we need seasoned leadership and von Hofe is the key to survival !! Credibility and trust need to be restored !
How many more delays/excuses/note conversions are acceptable ??
(2)
(1)Scroll down for more posts ▼
